Bactericidal activity of vancomycin in cerebrospinal fluid

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1932-1934

  Nagl, Markus ^a   Neher, Claudia ^a   Hager, Josef ^b   Pfausler, Bettina ^b   Schmutzhard, Erich ^b   Allerberger, Franz ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BRAIN VENTRICULITIS; CASE REPORT; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0032865156     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1932     Document Type: Article

References (13)

1. Allerberger, F., and I. Klare. 1999. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 43:211-217.
2. Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p. 52-111. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, Md.
3. Arroyo, J. C., and E. A. Quindlen. 1983. Accumulation of vancomycin after intraventricular infusions. South. Med. J. 76:1554-1555.
4. Bayston, R., C. A. Hart, and M. Barnicoat. 1987. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J. Neurol. Neurosurg. Psychiatry 50:1419-1423.
5. Cooper, G. C., and D. B. Given. 1986. Vancomycin, a comprehensive review of 30 years of clinical experience. Park Row Publishers, New York, N.Y.
6. Flandrois, J. P., G. Fardel, and G. Carret. 1988. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob. Agents Chemother. 32:454-457.
7. Guggenbichler, J. P., G. Menardi, and J. Hager. 1987. Antimicrobial therapy of bacterial meningitis in premature and newborn infants and shunt infections, p. 41-57. In J. P. Guggenbichler (ed.), New aspects for treatment with fosfomycin. Springer, Vienna, Austria.
8. Haworth, C. S., M. W. Sobieski, W. M. Scheld, and T. S. Park. 1990. Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits. Antimicrob. Agents Chemother. 34:245-251.
9. Kureishi, A., P. J. Jewesson, K. H. Bartlett, C. D. Cole, and A. W. Chow. 1990. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. Antimicrob. Agents Chemother. 34:1642-1647.
10. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Pfausler, B., H. P. Haring, A. Kampfl, J. Wissel, M. Schober, and E. Schmutzhard. 1997. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin. Infect. Dis. 25:733-735.
12. Swayne, R., A. Rampling, and S. W. Newsom. 1987. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J. Antimicrob. Chemother. 19:249-253.
13. Verbist, L. 1987. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci. Antimicrob. Agents Chemother. 31:340-342.